Watson recalls cardiac arrhythmia drug
Watson Pharmaceuticals announced that one lot of 100-count bottles of Propafenone HCL 225 mg tablets, a drug used to treat cardiac arrhythmias, is being voluntarily recalled in the U.S. at the consumer level as a precautionary measure.

The lot is being recalled because some tablets may contain higher levels of the active ingredient than specified, according to the Corona, Calif.-based Watson.

The affected lot of Propafenone HCL (Rytmonorm) tablets was shipped to U.S. customers between Oct. 15, 2008 and Nov. 26, 2008-no other strengths or lots were affected, Watson said. The company has notified the FDA of the recall.

Propafenone is used to treat cardiac arrhythmias. It has a narrow therapeutic index, so some patients who are particularly sensitive to small variations in dose may experience potentially serious side effects, including arrhythmias or low blood pressure. Consequently, as a precautionary measure, Watson is recalling this one lot to the consumer level to minimize any potential risk to patients.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup